Home/Services

R&D; SERVICE PORTFOLIO

From design and validation
to reviewable research deliverables.

Independent modules and phased joint development, with clear questions, endpoints and deliverables to support an understandable collaboration process.

Explore service modulesDiscuss your project

EIGHT SERVICE MODULES

Choose the right modules
for your research.

Indicative timelines come from existing service plans and support initial discussion of routine projects. Feasibility, resources and complexity affect actual scheduling.

  1. Molecular identity and activity

    Define the question and objective

  2. Size, loading and stability

    Confirm structure and evaluate release

  3. Uptake and intracellular localization

    Payload activity and cell compatibility

  4. Localization, distribution and clearance

    Distinguish carrier and payload signals

  5. Defined endpoints and controls

    Clarify conclusions and their limits

Conceptual preclinical evaluation pathway; no measured data are shown. Designs depend on payloads, models and predefined endpoints.

Original illustration labels: Chinese. From carrier design to disease research, each stage addresses a different validation question.
S1

Delivery study design

Indicative timing1–2 weeks

Assess molecular properties, target organs and cells to propose carriers, modifications and an experimental framework.

Starting information
Molecule details, target cells, existing data and endpoints
Proposed deliverables
Delivery design, feasibility assessment and phased study recommendations
S2

Carrier design and preparation

Indicative timing2–4 weeks

Select scaffolds, synthesize or assemble carriers, modify ligands or responsive groups and record key preparation conditions.

Starting information
Payload properties, candidate approaches and sample requirements
Proposed deliverables
Carrier samples and preparation or synthesis records
S3

Characterization and stability

Indicative timing1–2 weeks

Evaluate particle size and distribution, zeta potential, loading, encapsulation, release and stability.

Starting information
Samples, available assays and proposed measurements
Proposed deliverables
Characterization data, interpretation and methods
S4

In vitro delivery evaluation

Indicative timing2–4 weeks

Study uptake, localization, preliminary compatibility, responsive release and relevant functional readouts.

Starting information
Target cells, controls and assay endpoints
Proposed deliverables
In vitro report, original images and experimental data
S5

In vivo distribution and imaging

Indicative timing3–6 weeks

Plan in vivo imaging, organ-distribution quantification and preliminary pharmacokinetic studies in appropriate models.

Starting information
Administration route, labeling strategy, models and sampling plan
Proposed deliverables
Distribution and imaging report, quantitative data and records
S6

Disease-model efficacy studies

Indicative timing6–12 weeks

Define functional, biochemical and histological endpoints in models such as diabetic kidney disease and acute or chronic kidney injury.

Starting information
Disease model, dosing, primary and secondary endpoints
Proposed deliverables
Efficacy report, experimental records and data package
S7

Mechanism and omics support

Indicative timingProject-specific

Coordinate suitable analytical resources and key-pathway experiments to build mechanistic evidence.

Starting information
Mechanistic hypothesis, sample type and validation priorities
Proposed deliverables
Assay data, analysis notes and mechanism-validation materials
S8

Research output support

Indicative timingProject-specific

Data organization, scientific figures, patent disclosure materials and technical pathway consultation.

Starting information
Available data, intended use and ownership arrangements
Proposed deliverables
Figures, data explanations and technical or pathway materials

Scope, timelines, pricing and resources are subject to a written project plan. Animal studies and specialized assays require confirmation of facilities, ethics and relevant qualifications.

FLEXIBLE COLLABORATION

From a single question
to a connected chain of evidence.

Choose a starting point based on existing work, and expand the scope as sufficient information becomes available.

Enter at any stage · Dashed links indicate optional next steps

  1. 01

    Early feasibility

    For molecules without a defined carrier approach. Begin with design and initial preparation or characterization, then use results to determine the next scope.

    Initial pathway defined
  2. 02

    Carrier evaluation and optimization

    For projects with candidate carriers. Build comparable data through stability, uptake or in vivo distribution modules.

    Based on evaluation results
  3. 03

    Joint development in disease contexts

    For projects with a defined hypothesis and endpoints. Connect in vitro work, in vivo distribution, efficacy and mechanistic studies in stages.

Milestone review: jointly decide whether to continue, revise or add validation using the available data.

DELIVERABLES THAT CAN BE REVIEWED

Deliver the conclusions
and the evidence behind them.

Agree on deliverables at initiation so partners can review data, understand methods and identify limitations.

Data and records

  • Agreed raw images, instrument outputs and experimental data
  • Key samples, batches and assay conditions
  • Processing and analysis methods, with statistical details where needed
  • Interpretation and limitations linked to project objectives

Methods and conclusions

  • Key protocols, controls and endpoint definitions
  • Unexpected findings, protocol changes and deviations
  • Reviewable figures and milestone reports
  • Recommendations and unresolved questions